Health Care & Life Sciences » Biotechnology | Eiger BioPharmaceuticals Inc.

Eiger BioPharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
67.00
153.00
11.00
23.00
41.00
54
Gross Income
67.00
153.00
11.00
23.00
41.00
54
SG&A Expense
19,897.00
32,865.00
12,961.00
46,097.00
41,479.00
50,993
EBIT
19,964.00
33,018.00
-
46,120.00
41,520.00
51,047
Unusual Expense
162.00
183.00
-
365.00
-
-
Non Operating Income/Expense
25.00
29.00
-
88.00
186.00
12
Interest Expense
59.00
741.00
350.00
690.00
1,524.00
2,329
Pretax Income
20,091.00
33,853.00
13,322.00
47,087.00
42,448.00
52,391
Consolidated Net Income
20,091.00
33,853.00
13,322.00
47,087.00
42,448.00
52,391
Net Income
19,995.00
33,853.00
13,322.00
47,087.00
42,448.00
52,391
Net Income After Extraordinaries
16,890.00
33,853.00
13,322.00
47,087.00
42,448.00
52,391
Net Income Available to Common
20,851.00
33,853.00
13,322.00
47,087.00
42,448.00
52,391
EPS (Basic)
19.42
27.30
62.19
7.84
4.86
3.82
Basic Shares Outstanding
1,233.30
1,240.20
214.20
6,007.00
8,727.90
13,711
EPS (Diluted)
19.42
27.30
62.19
7.84
4.86
3.82
Diluted Shares Outstanding
1,233.30
1,240.20
214.20
6,007.00
8,727.90
13,711
EBITDA
19,897.00
32,865.00
12,961.00
46,097.00
41,479.00
50,993
Non-Operating Interest Income
69.00
118.00
-
-
410.00
997
Minority Interest Expense
96.00
-
-
-
-
-
Preferred Dividends
856.00
-
-
-
-
-

About Eiger BioPharmaceuticals

View Profile
Address
2155 Park Boulevard
Palo Alto California 94306
United States
Employees -
Website http://www.eigerbio.com
Updated 07/08/2019
Eiger BioPharmaceuticals, Inc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for orphan diseases. It focuses on product candidates for the treatment of orphan diseases such as Sarasar, Pegylated Interferon Lambda, Exendin 9-39, and Ubenimex. The company was founded by David A.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.